SanaCurrents on Precision Bio’s (DTIL) second-generation ‘stealth” CAR T cell therapy in cancer
Precision Biosciences, Inc. (NASDAQ:DTIL) Probability Sentiment SUMMARY While a handful of autologous CAR T cell [...]
SanaCurrents on Aadi Bio’s (AADI) expansion of nab-Sirolimus to solid tumor cancers
Aadi Bioscience, Inc. (NASDAQ:AADI) Probability Sentiment SUMMARY Shortly after listing in mid-2021, Aadi Bioscience, Inc. [...]
SanaCurrents on Syndax’s (SNDX) rising drug to treat rare, acute leukemias
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Probability Sentiment SUMMARY Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is advancing the small [...]
SanaCurrents on X4 Pharma’s (XFOR) small molecule to treat chronic neutropenia
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Probability Sentiment SUMMARY X4 Pharmaceuticals, Inc.’s (NASDAQ:XFOR) mavorixafor posted impressive clinical [...]
SanaCurrents on PDUFA decision for Tarsus’ (TARS) drug to treat dry eye caused by mites
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Probability Sentiment SUMMARY Staying focused on an FDA approval paid off [...]
SanaCurrents on Cyteir’s (CYT) push for CYT-0851 in Triple Negative Breast Cancer
Cyteir Therapeutics, Inc. (NASDAQ:CYT) Probability Sentiment SUMMARY Cyteir Therapeutics (NASDAQ:CYT) listed in June 2021, raising [...]
SanaCurrents on Seres’ (MCRB) fast follower microbiome treatment to prevent recurrent C. difficile infection (rCDI)
Seres Therapeutics, Inc. (NASDAQ:MCRB) Probability Sentiment SUMMARY Research in human microbiome treatments picked up rapidly [...]
SanaCurrents on ReNovoRx’s (RNXT) drug-device treatment for pancreatic cancer
Renovorx, Inc. (NASDAQ:RNXT) Probability Sentiment SUMMARY While pancreatic cancer has attracted many recent drug candidates [...]